Enhanced Drug Dissolution Research Articles

Formulation and Evaluation of Fast Dissolving Buccal Patch of Olmesartan Medoxomil

Now days tablet dosage forms are supplanted by new drug delivery system because of problems like hepatic metabolism, GI toxicity and enzymatic degradation which leads to non-compliance and ineffective therapy. These problems can be overcome by formulating the drug into fast dissolving buccal patches for oromucosal absorption with fast onset of action and improved bioavailability. In present work the fast dissolving buccal patches of Olmesartan medoxomil was prepared by solvent casting method using HPMC E5, HPMC 3cps and HPMC K100 as a film formers and PEG 400 as plasticizer. The prepared patches were evaluated for weight, thickness, folding endurance, surface pH, disintegration time, in-vitro drug release and stability studies on optimized formulation. The thickness of the all patches was found in the range of 0.22 to 0.30 mm. The disintegration time was found up to 60 sec. and the folding endurance was up to 200. The in-vitro drug release was found to be up to 100% within 2 minutes. Thus the fast dissolving buccal patch of Olmesartan medoxomil was successfully formulated to achieve a safe, rapid and effective dosage form with enhanced drug dissolution and rapid antihypertensive therapy.

Nano-Sized Crystalline Drug Production by Milling Technology

Nano-formulation of poorly water-soluble drugs has been developed to enhance drug dissolution. In this review, we introduce nano-milling technology described in recently published papers. Factors affecting the size of drug crystals are compared based on the preparation methods and drug and excipient types. A top-down approach using the comminution process is a method conventionally used to prepare crystalline drug nanoparticles. Wet milling using media is well studied and several wet-milled drug formulations are now on the market. Several trials on drug nanosuspension preparation using different apparatuses, materials, and conditions have been reported. Wet milling using a high-pressure homogenizer is another alternative to preparing production-scale drug nanosuspensions. Dry milling is a simple method of preparing a solid-state drug nano-formulation. The effect of size on the dissolution of a drug from nanoparticles is an area of fundamental research, but it is sometimes incorrectly evaluated. Here, we discuss evaluation procedures and the associated problems. Lastly, the importance of quality control, process optimization, and physicochemical characterization are briefly discussed.

RETRACTED ARTICLE: Meloxicam Taste-Masked Oral Disintegrating Tablet with Dissolution Enhanced by Ion Exchange Resins and Cyclodextrin

The purpose of this study was to develop taste-masked oral disintegrating tablets (ODTs) using the combination of ion exchange resin and cyclodextrin, to mask the bitter taste and enhance drug dissolution. Meloxicam (MX) was selected as a model drug with poor water solubility and a bitter taste. Formulations containing various forms of MX (free drug, MX-loaded resin or resinate, complexes of MX and 2-hydroxypropyl-β-cyclodextrin (HPβCD) or MX/HPβCD complexes, and a mixture of resinate and MX/HPβCD complexes) were made and tablets were prepared by direct compression. The ODTs were evaluated for weight variation, thickness, diameter, hardness, friability, disintegration time, wetting time, MX content, MX release, degree of bitter taste, and stability. The results showed that thickness, diameter, weight, and friability did not differ significantly for all of these formulations. The tablet hardness was approximately 3 kg/in.(2), and the friability was less than 1%. Tablets formulated with resinate and the mixture of resinate and MX/HPβCD complexes disintegrated rapidly within 60 s, which is the acceptable limit for ODTs. These results corresponded to the in vivo disintegration and wetting times. However, only tablets containing the mixture of resinate and MX/HPβCD complexes provided complete MX dissolution and successfully masked the bitter taste of MX. In addition, this tablet was stable at least 6 months. The results from this study suggest that the appropriate combination of ion exchange resin and cyclodextrin could be used in ODTs to mask the bitter taste of drug and enhance the dissolution of drugs that are weakly soluble in water.

Combination of lactose (as a carrier) with Cremophor® EL (as a liquid vehicle) to enhance dissolution of griseofulvin

Abstract Liquisolid technique is an approach to enhance dissolution of hydrophobic drugs. Most of liquisolid formulations are prepared with microcrystalline cellulose as a carrier which is hydrophobic. Accordingly, this study aimed to replace this hydrophobic carrier with a hydrophilic carrier (lactose) to be used in a combination with Cremophor® EL (as a liquid vehicle which has an inhibitory effect on P-glycoprotein) to improve dissolution of griseofulvin. The effects of carrier to coat ratio (R, ratios used were 10 and 20) and drug concentrations within liquid medications (15 and 20% w/w) on drug dissolution profiles were investigated. The dissolution profiles of liquisolid formulations and pure drug were compared. Solubility measurements, differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (FT-IR) were used for evaluation of physicochemical properties of griseofulvin in liquisolid powders. Enhanced drug release profiles were obtained due to increased drug solubility, wetting properties and surface area of drug particles available for dissolution. The rate of drug dissolution was significantly enhanced ( P P > 0.05) between formulations prepared with R -value of 10 and 20. The reduction in the drug crystallinity, as indicated by the DSC data, may be the reason for the enhanced drug dissolution from liquisolid powders. The combination of lactose and Cremophor® EL allows the production of liquisolid formulations with low unit dose powder weights.

Effect of excipients on dissolution enhancement of aceclofenac solid dispersions studied using response surface methodology: a technical note

The aim of present study was to enhance the dissolution rate of poorly water-soluble drug aceclofenac by solid dispersion technique using corn starch, dicalcium phosphate, lactose, and microcrystalline cellulose as carriers. Solid dispersions were prepared by solvent wetting method using 3(2) full factorial design for each of the carrier. The prepared solid dispersions were evaluated for differential scanning calorimetry, X-ray diffraction, scanning electron microscopy, Fourier-transform infrared spectroscopy (FTIR), and angle of repose. In vitro dissolution studies were carried out in phosphate buffer (pH 7.5) and 0.1 N HCl (pH 1.2). The results of solid state characterization bring to view that in solid dispersions the crystalline drug gets converted to its amorphous form. FTIR study results indicated the absence of interaction between aceclofenac and carriers. For prepared solid dispersions, angle of repose was found to be in the range of 26.19° to 35.29°, which indicates good flowability. Enhanced drug dissolution was obtained with carrier in order lactose > corn starch > microcrystalline cellulose > dicalcium phosphate. Hence, these carriers could be used to enhance the dissolution rate of poorly water-soluble drug.

Polymer-free and polyvinylpirrolidone-based electrospun solid dosage forms for drug dissolution enhancement

Fast-release nano- and microfibres of lipophilic spironolactone were prepared in a continuous manner by electrostatic spinning, in which the application of polyvinylpyrrolidone K90 as matrix polymer enabled formation of solid solutions. However, instead of the anticipated immediate drug release, temporary precipitation was observed. The polyvinylpyrrolidone web gelled immediately after wetting, hindering drug diffusion and aiding the crystallisation of the solvated amorphous spironolactone. These local supersaturations could be successfully avoided by using hydroxypropyl-β-cyclodextrin. The dependence of fibre diameter and dissolution rate on the complexing agent–polymer ratio was also studied. A small addition of hydroxypropyl-β-cyclodextrin proved enough for a dramatic release rate enhancement even in the case of high drug loaded formulations. Transmission Raman spectroscopy, differential scanning calorimetry and X-ray powder diffraction showed that the drug was totally amorphised during processing in all formulations. Polymer-free hydroxypropyl-β-cyclodextrin fibres containing spironolactone were also electrospun from an ethanolic solution, which is a new way of dissolution improvement in the case of poorly water-soluble drugs. This novel approach ensured nearly total drug release in a minute, making the system a suitable age-appropriate orally dissolving formulation.

Design and development of liquisolid compact of candesartan cilexetil to enhance dissolution

BackgroundCandesartan cilexetil is an angiotensin-II receptor antagonist used for the treatment of hypertension. It is hydrophobic drug which belongs to BCS class II and its half life is 5.1 h with 15–40% bioavailability. Attempt had made to investigate the use of liquisolid technique in improving the dissolution of candesartan cilexetil in a solid dosage form. MethodsThe liquisolid tablets were formulated by using Tween 80, as liquid vehicle, microcrystalline cellulose as a carrier material, silica as a coating material and sodium starch glycolate used as a superdisintegrant. The new mathematical model and 32 full factorial design was utilized to formulate various liquisolid powder systems. Result and discussionAll prepared liquisolid batches were subjected to, weight variation, drug content uniformity, hardness, friability test, disintegration test and dissolution tests. Liquisolid system is also tested for DSC, XRD and IR .All the tested liquisolid tablet formulations showed higher drug dissolution than the conventional, directly compressed tablet. ConclusionDSC and XRD study suggested loss of candesartan cilexetil crystallinity upon liquisolid formulation which was further confirmed by SEM, it indicates that drug is held within the powder substrate in a solubilized, almost molecularly dispersed state, which lead to the enhanced drug dissolution properties.

Dissolution Properties and Physical Characterization of Telmisartan–Chitosan Solid Dispersions Prepared by Mechanochemical Activation

Solid dispersion systems of telmisartan (a poorly water-soluble antihypertension drug) with biopolymer carrier chitosan have been investigated in this study. The mechanism of solubilization of chitosan for drug has been studied. In addition, the influence of several factors was carefully examined, including the preparation methods, the drug/carrier weight ratios, and the milling time. Drug dissolution and physical characterization of different binary systems were studied by in vitro dissolution test, particle size distribution, Fourier transform infrared spectroscopy, differential scanning calorimetry, powder X-ray diffractometry, and scanning electron microscopy. The results presented that the weak basic property of chitosan appeared as the main driving force for the drug dissolution enhancement. Other effects such as decreased drug crystallinity and size played a positive contributory role. Among the preparation methods, cogrinding was the best method showing strong drug amorphization, reduced particle size, and enhanced dissolution. The drug dissolution markedly improved with increasing the amount of chitosan in solid mixtures. As a result, a significant effect of chitosan increasing telmisartan dissolution has been demonstrated, and cogrinding in a roll ball mill was the best way to prepare solid dispersions, which had high degree of uniformity in drug content and had a practical application in manufacturing.

Serum Concentrations and Hypoglycemic Effect of Gliclazide:Crosspovidone Solid Dispersion on Streptozotocin Induced Diabetic Rats

Gliclazide is practically insoluble in water and its GI absorption is limited by its dissolution rate. Our previously published works indicated that preparing gliclazide-crosspovidone solid dispersion in the drug/ carrier ratio of 1:1 using cogrinding technique is able to enhance drug dissolution rate. The coground of gliclazide-crosspovidone was administrated to the rats and the hypoglycemic effects of pure drug, a physical mixture and the coground were considered in 3 groups of rats weighing 200-250 g (n=6). The rats were made diabetic by single intravenous administration of streptozotocin (60 mg/kg). Each of the rats received a single dose of gliclazide (equivalent to 40 mg/kg) as pure drug, physical mixture and coground in an aqueous suspension. Glucose level was assessed via glucometer after collecting the blood samples from tail vein. Gliclazide concentration in plasma was assessed applying high pressure liquid chromatography. According to 1-way ANOVA, Student-Newman-Keuls test, the coground revealed enhanced hypoglycemic effects as well as higher serum gliclazide concentration relative to pure drug and its corresponding physical mixture in the all sampling times. The area under serum glucose concentration curve vs. time for the pure gliclazide, physical mixture and coground formulations were 3 090.5±79, 3 018.8±96 and 2 374.0±73 mg.h/dl, respectively. Correspondingly, their area under serum gliclazide concentration curve vs. time were 1 171.8±156.8, 1 379.5±96.2 and 4 827.7±637.5 μg.h/ml. It follows that; formulation of gliclazide-crosspovidone coground is able to improve oral absorption of the drug.

NANO-SIZED SOLID DISPERSION OF A POORLY WATER-SOLUBLE DRUG

Purposes: Aims of this study are dissolution enhancement of a poorly water-soluble drug by nano-sized solid dispersion and investigation of machenism of drug release from the solid dispersion. A drug for osteoporosis treatment was used as the model drug in the study. Methods: melting method was used to prepare the solid dispersion. Drug dissolution rate was investigated at pH 1.2 and pH 6.8. Drug crystallinity was studied using differential scanning calorimetric and powder X-ray diffraction. In addition, droplet size and contact angle of drug were determined to elucidate mechanism of drug release. Results: Drug dissolution from the solid dispersion was significantly increased at pH 1.2 and pH 6.8 as compared to pure drug. Drug crystallinity was changed to partially amorphous. Also dissolution enhancement of drug was due to the improved wettability. The droplet size of drug was in the scale of nano-size when solid dispersion was dispersed in dissolution media. Conclusions: nano-sized solid dispersion in this research was a successful preparation to enhance bioavailability of a poorly water-soluble drug by mechanisms of crystal changes, particle size reduction and increase of wet property.

Spironolactone release from liquisolid formulations prepared with Capryol™ 90, Solutol® HS-15 and Kollicoat® SR 30 D as non-volatile liquid vehicles

The purpose of the study is to enhance dissolution of spironolactone as a model hydrophobic drug through application of liquisolid technology. Spironolactone is prepared as liquisolid formulations, and its dissolution property is evaluated and compared to that of conventional spironolactone tablets and pure spironolactone. Three non-volatile liquid vehicles were used in the design of spironolactone liquisolid formulations, Capryol™ 90, Synperonic® PE/L61 in combination with Solutol® HS-15 at a ratio of 1:1, and Kollicoat® SR 30 D. Spironolactone liquisolid formulations were tested according to British Pharmacopoeia (BP) quality control tests. Furthermore, the prepared liquisolid powder formulations were evaluated via differential scanning calorimetry (DSC), Fourier transform infrared (FT-IR) and scanning electron microscopy. Also, liquisolid formulations were subjected to testing of storage stability at high relative humidity. The results indicated that most of liquisolid tablets met the BP requirements. Dissolution results indicate that release of spironolactone was significantly increased (P<0.05) through liquisolid formulations, compared to pure drug. Liquisolid powder formulations formulated from a combination of Synperonic® PE/L61–Solutol® HS-15 showed highest dissolution. DSC thermograms from liquisolid formulations revealed that drug endothermic peak was disappeared after processing. Dissolution, DSC and FT-IR data after storage demonstrated that there were no significant changes in the formulations after storage. In conclusion, the liquid vehicles used within spironolactone liquisolid formulations enhanced drug dissolution rate.

Spray coating as a powerful technique in preparation of solid dispersions with enhanced desloratadine dissolution rate

Solid dispersion systems have been widely used to enhance dissolution rate and oral bioavailability of poorly water-soluble drugs. However, the formulation process development and scale-up present a number of difficulties which has greatly limited their commercial applications. In this study, solid dispersions (SDs) of desloratadine (DSL) with povidone (PVP) and crospovidone (cPVP) were prepared by spray coating technique. The process involved the spray application of 96% ethanol solution of DSL and PVP/cPVP, and subsequent deposition of the coprecipitates onto microcrystalline cellulose pellets during drying by air flow in a mini spray coater. The results from the present study demonstrated that the spray coating process is efficient in preparing SDs with enhanced drug dissolution rate and it is highly efficient in organic solvent removal. Both PVP and cPVP greatly improved drug dissolution rate by SDs, with PVP showing better solubilization capability. Very fast drug dissolution rate is achieved from SDs containing PVP regardless of differences in K grade. SD with smaller particles of cPVP have higher drug dissolution rate in comparison to the cPVP with larger particles. Results from physical state characterization indicate that DSL in SDs exist in the amorphous (high free-energy) state which is probably stabilized by PVP/cPVP. After 6-month accelerated stability study, DSL remains amorphous, while PVP and cPVP act as anti-plasticizing agents, offering efficient steric hindrance for nucleation and crystal growth.

Liquisolid technique to enhance and to sustain griseofulvin dissolution: Effect of choice of non-volatile liquid vehicles

Liquisolid systems were originally designed to enhance dissolution of hydrophobic drugs. Recently, the same technique was explored to control drug release via hydrophobic carriers. This work aimed to study the effects of different liquid vehicles on release characteristics of griseofulvin as a model hydrophobic drug. Fast dissolution tablets were prepared using three different non-ionic surfactants namely Cremophor®EL, Synperonic®PE/L61 and Capryol™ 90, on the contrary Kollicoat®SR 30D was used for production of grieseofulvin sustained release formulations. Avicel® PH102 and Cab-O-Sil® M5 were used as carrier and coat materials, respectively. The effect of formulation parameters, such as drug concentration and carrier to coat ratio, on enhancing drug dissolution was explored. Drug concentrations of 20% and 40% (w/w), and R-values (carrier to coat ratio) of 10 and 20 were used. The mathematical model was utilized to formulate liquisolid powder systems. All fast release liquisolid formulations showed higher percentage drug dissolution efficiency (%DE) than conventional directly compacted tablets. Cremophor®EL showed the best dissolution enhancement with %DE of about 90%, compared to only 23% for conventional tablets; DSC data suggested loss of griseofulvin crystallinity and thermal behavior. Kollicoat® SR 30D retarded the drug release even in the presence of hydrophilic carrier; DSC data suggested that only small fraction of the drug was present in the molecular state within the system. The used liquisolid vehicles showed promise to enhance and to control (depend on the choice of the liquid vehicle) the release of griseofulvin from liquisolid compacts.

Sucrose esters as natural surfactants in drug delivery systems—A mini-review

Sucrose esters (SEs) are widely used in the food and cosmetic industries and there has recently been great interest in their applicability in different pharmaceutical fields. They are natural and biodegradable excipients with well-known emulsifying and solubilizing behavior. Currently the most common pharmaceutical applications of SEs are for the enhancement of drug dissolution and drug absorption/permeation, and in controlled-release systems. Although the number of articles on SEs is continuously increasing, they have not yet been widely used in the pharmaceutical industry. The aim of this review is to discuss and summarize some of the findings and applications of SEs in different areas of drug delivery. The article highlights the main properties of SEs and focuses on their use in pharmaceutical technology and on their regulatory and toxicological status.

Emerging trends in the stabilization of amorphous drugs

The number of active pharmaceutical substances having high therapeutic potential but low water solubility is constantly increasing, making it difficult to formulate these compounds as oral dosage forms. The solubility and dissolution rate, and thus potentially the bioavailability, of these poorly water-soluble drugs can be increased by the formation of stabilized amorphous forms. Currently, formulation as solid polymer dispersions is the preferred method to enhance drug dissolution and to stabilize the amorphous form of a drug. The purpose of this review is to highlight emerging alternative methods to amorphous polymer dispersions for stabilizing the amorphous form of drugs. First, an overview of the properties and stabilization mechanisms of amorphous forms is provided. Subsequently, formulation approaches such as the preparation of co-amorphous small-molecule mixtures and the use of mesoporous silicon and silica-based carriers are presented as potential means to increase the stability of amorphous pharmaceuticals.

Rapidly absorbed orodispersible tablet containing molecularly dispersed felodipine for management of hypertensive crisis: Development, optimization and in vitro/in vivo studies

A liquisolid orodispersible tablet of felodipine, a BCS Class II drug, was developed to improve drug dissolution and absorption through the buccal mucosa for management of hypertensive crisis. A 24 full-factorial design was applied to optimize felodipine liquisolid systems (FLSs) having acceptable flow properties and possessing enhanced drug dissolution rates. Four formulation variables; The liquid type, X1 (PG or PEG), drug concentration, X2 (10% and 20%), type of coat, X3 (Aerosil® and Aeroperl®) and excipients ratio, X4 (10 and 20) were included in the design. The systems were assessed for dissolution and flow properties. Following optimization, the formulation components (X1, X2, X3 and X4) were PEG, 10%, Aerosil® and 20, respectively. The optimized FLS was compressed into felodipine liquisolid orodispersible tablet using Prosolv® as carrier material (FLODT-2). The in vitro and in vivo disintegration times of FLODT-2 were 9 and 7 s, respectively. The in vivo pharmacokinetic study using human volunteers showed a significant increase in dissolution and absorption rates of the formulation of FLODT-2 compared to soft gelatin capsules filled with felodipine solution in PEG under the same conditions. Our results proposed that the optimized FLODT formulation could be promising to manage hypertensive crisis.

In vitro-in vivo evaluation of fast-dissolving tablets containing solid dispersion of pioglitazone hydrochloride.

Investigation of in vitro/in vivo behavior of fast-dissolving tablets containing solid dispersions of pioglitazone hydrochloride (PIO) is the focus of the present research work. The effect of various hydrophilic polymers on the aqueous solubility of PIO was studied. Poly vinyl pyrrolidine K 30 (PVPK 30) carrier was selected and solid dispersions were prepared by various methods. Evaluation of solid dispersion for percentage yield, drug content, solubility, and Fourier Transform Infrared-indicated kneading method was most appropriate. Furthermore, the dissolution studies exhibited an enhancement in drug dissolution. One-way ANOVA of in vitro data suggested that there was significant (P ≤ 0.05) difference in dissolution profile of PIO solid dispersion when compared with pure drug and commercial product. Infrared spectroscopy, differential scanning calorimetry, and powder X-ray diffraction performed on solid dispersion indicated lack of physicochemical interaction between the drug and the carrier. The selected formulation is compressed into fast-dissolving tablets which were further evaluated for tablet properties and in vitro drug release. In vivo studies of pure drug, selected formulation, and marketed product were carried out in male Wistar rats and pharmacokinetic parameters were calculated using Kinetica software 2000. The best formulation has shown Tmax of 1 hour which was highly significant (P < 0.01) when compared with pure drug and marketed formulation. Therefore, the solid dispersions prepared by kneading method using PVPK 30 as hydrophilic carrier can be successfully used for improvement of dissolution of PIO and resulted in faster onset of action as indicated by in vivo studies.

Electrospun Borneol‐PVP Nanocomposites

The present work investigates the validity of electrospun borneol‐polyvinylpyrrolidone (PVP) nanocomposites in enhancing drug dissolution rates and improving drug physical stability. Based on hydrogen bonding interactions and via an electrospinning process, borneol and PVP can form stable nanofiber‐based composites. FESEM observations demonstrate that composite nanofibers with uniform structure could be generated with a high content of borneol up to 33.3% (w/w). Borneol is well distributed in the PVP matrix molecularly to form the amorphous composites, as verified by DSC and XRD results. The composites can both enhance the dissolution profiles of borneol and increase its physical stability against sublimation for long‐time storage by immobilization of borneol molecules with PVP. The incorporation of borneol in the PVP matrix weakens the tensile properties of nanofibers, and the mechanism is discussed. Electrospun nanocomposites can be alternative candidates for developing novel nano‐drug delivery systems with high performance.

Physicochemical characterisation, drug polymer dissolution and in vitro evaluation of phenacetin and phenylbutazone solid dispersions with polyethylene glycol 8000

Poor water solubility leads to low dissolution rate and consequently, it can limit bioavailability. Solid dispersions, where the drug is dispersed into an inert, hydrophilic polymer matrix can enhance drug dissolution. Solid dispersions were prepared using phenacetin and phenylbutazone as model drugs with polyethylene glycol (PEG) 8000 (carrier), by melt fusion method. Phenacetin and phenylbutazone displayed an increase in the dissolution rate when formulated as solid dispersions as compared with their physical mixture and drug alone counterparts. Characterisation of the solid dispersions was performed using differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR) and scanning electron microscopy (SEM). DSC studies revealed that drugs were present in the amorphous form within the solid dispersions. FTIR spectra for the solid dispersions of drugs suggested that there was a lack of interaction between PEG 8000 and the drug. However, the physical mixture of phenacetin with PEG 8000 indicated the formation of hydrogen bond between phenacetin and the carrier. Permeability of phenacetin and phenylbutazone was higher for solid dispersions as compared with that of drug alone across Caco‐2 cell monolayers. Permeability studies have shown that both phenacetin and phenylbutazone, and their solid dispersions can be categorised as well‐absorbed compounds. © 2011 Wiley‐Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:4281–4294, 2011

Preformulation studies on host–guest composites for oral administration of BCS class IV drugs: HTlc and furosemide

Oral administration of poorly soluble drugs represents a challenge for the pharmaceutical industries. This research proposes the realization of host–guests composites in which the model drug furosemide (FURO), labeled in class IV of BCS, was chosen as guest whereas hydrotalcite like compounds (HTlcs) were used as host materials. Two intercalation products, MgAl-HTlc-FURO and ZnAl-HTlc-FURO, were prepared and characterized. Once intercalated the drug is not organized as crystals but gives rise to a new product in which it is molecularly dispersed forming a molecular film that could be defined “shell-liquid state”, in the nanospaces of the interlayer region. In vitro release studies resulted that both intercalation products are able to promote drug dissolution enhancement, however, because of their different physicochemical properties MgAl-HTlc-FURO gave the best results. Then this product was submitted to supersaturation assay and physical stability studies revealed that drug molecular anions resist the hydrolytic attack and re-crystallization of FURO is prevented during storage conditions.